Merit has showcased a new radial compression product, Preludesync, on its website.
Lombard Medical’s portfolio of endovascular stent graft systems, Altura and Aorfix, were featured in scientific presentations at the 39th annual Charing Cross International Symposium (CX; 25–28 April, London, UK).
Significant success has been achieved in treating complex proximal aneurysms using a combination of fenestrated and branched graft devices, based on a report of prospectively studied patients with complex aortic aneurysm in the May edition of the Journal of Vascular Surgery.
Howard Rosen has joined Intact Vascular’s executive management team as vice president of marketing and business development. In this position, Rosen will lead the company’s efforts to prepare for commercialisation of its Tack Endovascular System for the repair of dissections following peripheral artery angioplasty.
Contego Medical has announced that it has received CE mark for its Vanguard IEP peripheral balloon angioplasty system with integrated embolic protection. The company intends to launch the Vanguard IEP system in Europe to endovascular specialists performing lower limb angioplasty procedures.
Twelve posters selected for presentation out of 68 posters displayed were carefully reviewed by the CX Abstract Board, who decided to award their prize of a free CX 2018 registration to (San Donato Milanese, Italy) for her poster, “Study and patient specific prediction of the fatigue behaviour of peripheral nitinol stent of the superficial femoral arteries through mathematical modelling”. One of four peripheral arterial posters, Mazzaccaro’s took an innovative approach to the subject at hand.
The CX Venous Workshop returned on Wednesday, bigger than ever before. With a new location in the Exhibition Hall and its own series of edited live case presentations, it continues to showcase innovative venous technology and offer delegates the chance to get hands-on with the latest advances in the arena. Expanding from previous years’ Venous Village to this year’s Venous City, the workshop has brought together delegates and demonstrators from all over the world to experience the state of the art.
For the first time, Day One of this year’s CX Venous Workshop included two edited case presentations (CX Venous Edited Cases). The standing-room only session gave delegates the opportunity to watch two innovative devices in action and quiz experienced surgeons on their top procedural tips.
First-time data presentation from the SWAN (Screening Women for Abdominal aNeurysms) project was heard at the 2017 Charing Cross Symposium (CX; 25–28 April, London, UK). The study, which used simulation to evaluate whether inviting women to be screened for abdominal aortic aneurysm would have clinical benefit, or be cost-effective, revealed that such a programme would yield a very small benefit. Further, such a screening programme would not be cost-effective in the UK context.
A “podium first” presentation of very long-term follow-up data from the EVAR 2 trials suggests that endovascular aneurysm repair (EVAR) fails to improve all-cause mortality, but reduces aneurysm-related mortality compared to no treatment in abdominal aortic aneurysm patients who are physically ineligible for open repair. The data were presented yesterday at CX and prompted a discussion on the dilemma of whether to offer, or withhold, EVAR in this group of frail patients in the light of these findings. The panel discussion then prompted a spontaneous show of hands in which delegates backed the idea of adopting a model of shared decision-making with frail patients who are in poor health when discussing EVAR or no treatment.
Medtronic has reported that its Endurant II abdominal aortic aneurysm (AAA) stent graft system continues to demonstrate long-term durability and consistent outcomes in a real-world setting. The five-year ENGAGE global registry data were presented for the first time at the 2017 CX Symposium in London, UK.
At the 2017 Charing Cross Symposium (CX; 25–28 April, London, UK), delegates heard brand new data for drug-coated balloons (DCBs) in “wider use” scenarios such as challenging lesions; one-year results for a novel DCB; and late-breaking data on downstream coating effects of various DCBs. Still, 84% of the CX audience said “no” in response to the question: are DCBs equally effective in all lesion subsets? There is still uncertainty in the therapeutic puzzle about which device in the endovascular armamentarium is best suited to treat which lesion.
Tuesday’s CX Aortic Edited Cases session featured exciting and engaging standing-room only case presentations, including Andrew Holden’s (Auckland, New Zealand) first-in-man implantation of the Ovation Alto (Endologix). Covering thoracic, juxtarenal and abdominal cases, the packed-out session explored innovative techniques, novel devices and a veritable array of practical tips and tricks, offering an invaluable resource for delegates.
Lombard Medical has now enrolled and treated the first patient in its global registry to evaluate its Altura endograft system.
The particular complexities of dealing with paediatric vessels were discussed in depth at Tuesday’s varied and informative CX Paediatric Vascular Emergencies and Case Presentations session. Covering topics as diverse as acute ischaemia from pre-term to infant and treatment for battlefield trauma in children, the session was one of the highlights of the day.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos